Novel and emerging therapies for B cell lymphoma

Table 2 Cellular therapies

Cellular therapy	N	Patient population	ORR	CR	Grade 3 CRS/NT	Grade 3 AE	Ref
ET190L1-Artemis^TM Therapy	21	DLBCL, FL,MCL, SLL/CLL, splenic MZL	52%	24%	None	Lymphopenia, neutropenia, tremor, fever, rash	[19]
Bispecific CAR (CD-19/CD-20)	7	DLBCL, ALL	60% (DLBCL)	40% (DLBCL)	None	None	[23]
Bispecific CAR (CD-19/CD-20)	6	DLBCL, FL, MCL,CLL	50%	33%	None	None	[24]
Bispecific CAR (CD-19/CD-22)	6	DLBCL, tFL, tMZL	80%	40%	1 patient (20%)—NT	Neutropenia, thrombocytopenia, hypophosphatemia, neurotoxicity	[25]
Armored CAR T cells	25	DLBCL ,CLL, tFL, FL, WM	72%	57%	2 patients (8%)—NT	Neurotoxicity	[26]
ACTR 087	7	r/r NHL	50%	33%	None	Neutropenia, leukopenia	[27]
ACTR 707	6	DLBCL, FL	NA	50%	None	Febrile neutropenia	[28]

Abbreviations: N number of patients, ORR overall response rate, CR complete response rate, CRS cytokine release syndrome, NT neurotoxicity, AE adverse events, DLBCL diffuse large B cell lymphoma, CLL chronic leukemic leukemia, tFL transformed follicular lymphoma, FL follicular lymphoma, WM Waldenström’s macroglobulinemia, MCL mantle cell lymphoma, tMZL transformed marginal zone lymphoma, ALL acute lymphoblastic leukemia, NHL non-Hodgkin lymphoma, MZL marginal zone lymphoma, NA data unavailable

ISSN: 1756-8722